TOP TEN perturbations for 1553608_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553608_a_at
Selected probe(set): 1553607_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553608_a_at (1553607_at) across 6673 perturbations tested by GENEVESTIGATOR:

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):1.8646226
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):1.4997673
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.

LPS study 6 / vehicle (saline) treated alveolar macrophage cell sample

Relative Expression (log2-ratio):1.3555155
Number of Samples:6 / 6
Experimental LPS study 6
Alveolar macrophages obtained from contralateral lung segment of healthy volunteer exposed to LPS (4 ng/kg body weight) for 6 hours. LPS from Escherichia coli (diluted in 10 ml saline) was instilled into the contralateral lung by video bronchoscope. 6 hours after LPS challenge bronchoalveolar lavage was performed by rinsing the lungs 7 times with 20 ml prewarmed 0.9% saline (after instillation saline was immediately aspirated). Alveolar macrophages (CD71+ cells) were isolated from bronchoalveolar lavage fluid (BALF) using CD71 microbeads. Volunteers were all men, non-smokers and physically healthy (tested by physical examination, blood and urine investigation, electrocardiogram and spirometry). ATC code:---
Control vehicle (saline) treated alveolar macrophage cell sample
Alveolar macrophages obtained from contralateral lung segment of healthy volunteer exposed to saline for 6 hours. Saline (10 ml) was instilled into the contralateral lung by video bronchoscope. 6 hours after vehicle challenge bronchoalveolar lavage was performed by rinsing the lungs 7 times with 20 ml prewarmed 0.9% saline (after instillation saline was immediately aspirated). Alveolar macrophages (CD71+ cells) were isolated from bronchoalveolar lavage fluid (BALF) using CD71 microbeads. Volunteers were all men, non-smokers and physically healthy (tested by physical examination, blood and urine investigation, electrocardiogram and spirometry).

HCC study 26 (tumor; TG/GG genotype) / HCC study 26 (non-tumor; TG/GG genotype)

Relative Expression (log2-ratio):1.10324
Number of Samples:10 / 10
Experimental HCC study 26 (tumor; TG/GG genotype)
Liver tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).
Control HCC study 26 (non-tumor; TG/GG genotype)
Liver non-tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).

HCC study 26 (tumor; TG/GG genotype) / HCC study 26 (tumor; TT genotype)

Relative Expression (log2-ratio):1.1009808
Number of Samples:10 / 10
Experimental HCC study 26 (tumor; TG/GG genotype)
Liver tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) rs8099917 TG/GG (minor) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 1:9; age: 60 (49-75); cirrhosis (yes:no) 5:5; History of IFN therapy (yes:no) 5:5; Child-Pugh class (A:B) 10:0; Tumor no. (1:2:3) 7:0:3; Tumor size (mm) 28.5 (17-38).
Control HCC study 26 (tumor; TT genotype)
Liver tumor tissue resected from patients with hepatocellular carcinoma, with Interleukin-28B (Il28B) TT (major) genotype. HCC diagnosis was based predominantly on image analysis (CT and/or MRI and abdominal angiography with CT imaging in the arterial and portal flow phase). Patients inclusion criteria were: a) Child-Pugh class A or B; b) the presence of up to 3 tumors, each 3 cm or less; c) HCV infection (positive for HCV RNA, patients with sustained viral response were excluded); d) radical treatment by either surgical resection or RFA; and e) availability of blood samples for genetic analyses. Patients clinical features were: Sex (male:female) 4:6; age: 70 (47-78); cirrhosis (yes:no) 7:3; History of IFN therapy (yes:no) 4:6; Child-Pugh class (A:B) 9:1; Tumor no. (1:2:3) 9:1:0; Tumor size (mm) 34 (14-62).

septic shock study 3 (D2; non-survivor) / septic shock study 3 (D2; survivor)

Relative Expression (log2-ratio):1.1009712
Number of Samples:8 / 12
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control septic shock study 3 (D2; survivor)
Blood samples from patients (survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).

sarcoidosis study 4 / normal PBMC sample

Relative Expression (log2-ratio):1.0784984
Number of Samples:38 / 20
Experimental sarcoidosis study 4
Peripheral blood mononuclear cells (PBMC´s) obtained from patients with pulmonary sarcoidosis. Exclusion criteria were other concurrent systemic inflammatory conditions. Sarcoidosis was diagnosed according to established criteria (Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (Ers) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.AmJ Respir Crit CareMed 1999;160:736–755).
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMC´s) derived from healthy controls. Control subjects had no lung disease or any other significant medical conditions.

interstitial lung disease study 5 (HP) / normal PBMC sample

Relative Expression (log2-ratio):0.9811816
Number of Samples:6 / 20
Experimental interstitial lung disease study 5 (HP)
Peripheral blood mononuclear cells (PBMC´s) obtained from patients with hypersensitive pneumonitis (HP).
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMC´s) derived from healthy controls. Control subjects had no lung disease or any other significant medical conditions.

GM-CSF study 1 (1ng/ml) / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):0.91600037
Number of Samples:10 / 10
Experimental GM-CSF study 1 (1ng/ml)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h.
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

systemic lupus erythematosus study 3 / normal blood sample

Relative Expression (log2-ratio):0.9092884
Number of Samples:89 / 30
Experimental systemic lupus erythematosus study 3
Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE).
Control normal blood sample
Blood samples from healthy individuals.

Organism: Homo sapiens
Gene: 1553608_a_at
Selected probe(set): 204194_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553608_a_at (204194_at) across 6673 perturbations tested by GENEVESTIGATOR:

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):4.2447033
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-3.90722
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.755869
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):3.7195187
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.6010199
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):3.3364353
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

actinomycin D study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):-3.3193874
Number of Samples:3 / 3
Experimental actinomycin D study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.1150932
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 4 (A/H1N1) / mock infected A549 cell sample

Relative Expression (log2-ratio):-2.9919386
Number of Samples:3 / 6
Experimental influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.
Control mock infected A549 cell sample
Human A549 carcinoma cells mock infected (A/H1N1). Sample was taken at 0 hours post-infection.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):2.6898708
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.